Growth factor regulatory system: a new system for not truly recognized organisms

  • 1 Accesses

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA


  1. Fu, X., Shen, Z., Chen, Y., Xie, J., Guo, Z., Zhang, M., and Sheng, Z. (1998). Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns. Lancet 352, 1661–1664.

  2. Fu, X., Sun, X., Li, X., and Sheng, Z. (2001). Dedifferentiation of epidermal cells to stem cells in vivo. Lancet 358, 1067–1068.

  3. Haffner, D., Emma, F., Eastwood, D.M., Duplan, M.B., Bacchetta, J., Schnabel, D., Wicart, P., Bockenhauer, D., Santos, F., Levtchenko, E., et al. (2019). Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15, 435–455.

  4. Itoh, N., and Ornitz, D.M. (2011). Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 149, 121–130.

  5. Jonker, J.W., Suh, J.M., Atkins, A.R., Ahmadian, M., Li, P., Whyte, J., He, M., Juguilon, H., Yin, Y.Q., Phillips, C.T., et al. (2012). A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485, 391–394.

  6. Kale, S., Biermann, S., Edwards, C., Tarnowski, C., Morris, M., and Long, M.W. (2000). Three-dimensional cellular development is essential for ex vivo formation of human bone. Nat Biotechnol 18, 954–958.

  7. Li, S., Zhu, Z., Xue, M., Yi, X., Liang, J., Niu, C., Chen, G., Shen, Y., Zhang, H., Zheng, J., et al. (2019). Fibroblast growth factor 21 protects the heart from angiotensin II-induced cardiac hypertrophy and dysfunction via SIRT1. Biochim Biophys Acta Mol Basis Dis 1865, 1241–1252.

  8. Li, X. (2019). The FGF metabolic axis. Front Med 13, 511–530.

  9. Lin, Z., Pan, X., Wu, F., Ye, D., Zhang, Y., Wang, Y., Jin, L., Lian, Q., Huang, Y., Ding, H., et al. (2015). Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation 131, 1861–1871.

  10. Lin, Z., Tian, H., Lam, K.S.L., Lin, S., Hoo, R.C.L., Konishi, M., Itoh, N., Wang, Y., Bornstein, S.R., Xu, A., et al. (2013). Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 17, 779–789.

  11. Muggianu, F., Benso, A., Bardini, R., Hu, E., Politano, G., and Carlo, S.D. (2018). Modeling biological complexity using Biology System Description Language (BiSDL). In 2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). 1, 713–717.

  12. Ott, S.M. (2015). Bone cells, sclerostin, and FGF23: what’s bred in the bone will come out in the flesh. Kidney Int 87, 499–501.

  13. Pan, X., Shao, Y., Wu, F., Wang, Y., Xiong, R., Zheng, J., Tian, H., Wang, B., Wang, Y., Zhang, Y., et al. (2018). FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1–7) axis in mice. Cell Metab 27, 1323–1337.e5.

  14. Suh, J.M., Jonker, J.W., Ahmadian, M., Goetz, R., Lackey, D., Osborn, O., Huang, Z., Liu, W., Yoshihara, E., van Dijk, T.H., et al. (2014). Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 513, 436–439.

  15. Yie, J., Wang, W., Deng, L., Tam, L.T., Stevens, J., Chen, M.M., Li, Y., Xu, J., Lindberg, R., Hecht, R., et al. (2012). Understanding the physical interactions in the FGF21/FGFR/β-Klotho complex: structural requirements and implications in FGF21 signaling. Chem Biol Drug Des 79, 398–410.

Download references


X.F. acknowledges the financial support from the National Natural Science Foundation of China (81830064 and 81721092) and the National Key R&D Program of China (2017YFC1103300). J.X. acknowledges financial support from the National Natural Science Foundation of China (81722028 and 81972150). X.L. acknowledges the financial support from the National Key R&D Program of China (2017YFA0506000).

Author information

Correspondence to Xiaokun Li or Xiaobing Fu.

Additional information

Compliance and ethics

The author(s) declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xiao, J., Lin, Z., Qin, H. et al. Growth factor regulatory system: a new system for not truly recognized organisms. Sci. China Life Sci. (2020) doi:10.1007/s11427-019-1590-x

Download citation